These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9824618)

  • 1. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.
    Haas C; Ertel C; Gerhards R; Schirrmacher V
    Int J Oncol; 1998 Dec; 13(6):1105-15. PubMed ID: 9824618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
    Fournier P; Zeng J; Von Der Lieth CW; Washburn B; Ahlert T; Schirrmacher V
    Int J Oncol; 2004 Mar; 24(3):623-34. PubMed ID: 14767547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.
    Termeer CC; Schirrmacher V; Bröcker EB; Becker JC
    Cancer Gene Ther; 2000 Feb; 7(2):316-23. PubMed ID: 10770642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells
    Rangaswamy US; Wang W; Cheng X; McTamney P; Carroll D; Jin H
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
    Haas C; Schirrmacher V
    Cancer Immunol Immunother; 1996 Nov; 43(3):190-4. PubMed ID: 9001573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
    Ertel C; Millar NS; Emmerson PT; Schirrmacher V; von Hoegen P
    Eur J Immunol; 1993 Oct; 23(10):2592-6. PubMed ID: 8405059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
    Jarahian M; Watzl C; Fournier P; Arnold A; Djandji D; Zahedi S; Cerwenka A; Paschen A; Schirrmacher V; Momburg F
    J Virol; 2009 Aug; 83(16):8108-21. PubMed ID: 19515783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
    Jurianz K; Haas C; Hubbe M; Ertel C; Brunner G; Altevogt P; Schirrmacher V; Vonhoegen P
    Int J Oncol; 1995 Sep; 7(3):539-45. PubMed ID: 21552872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
    Morrison TG; McGinnes LW
    Virology; 1989 Jul; 171(1):10-7. PubMed ID: 2545025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene].
    Mi ZQ; Jin NY; Sun YC; Li X; Lian H; Li J; Guan GF
    Ai Zheng; 2004 Aug; 23(8):910-3. PubMed ID: 15301713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
    Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C
    Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus.
    Zeng J; Fournier P; Schirrmacher V
    Virology; 2002 May; 297(1):19-30. PubMed ID: 12083832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant-attenuated
    Ding K; Shang K; Yu ZH; Yu C; Jia YY; He L; Liao CS; Li J; Zhang CJ; Li YJ; Wu TC; Cheng XC
    J Vet Sci; 2018 Mar; 19(2):232-241. PubMed ID: 29032660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.
    Schirrmacher V; Griesbach A; Ahlert T
    Int J Oncol; 2001 May; 18(5):945-52. PubMed ID: 11295039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with virus-modified tumor cells.
    Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
    Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
    Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
    Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.